Products

“We want to remain a step ahead. That’s why we actively seek out or independently develop products which conform to the latest findings, and guarantee patients long-term use without side effects impacting their health.”

GLYCOMACROPEPTIDES (GMP) – the future of PKU/HPA dietary therapy

We’re proud that American company Ajinomoto Cambrooke, leader and global innovator in food for special medical purposes, chose our company to collaborate with.

Ajinomoto Cambrooke was the first company in the world to develop products based on GMP (the GLYTACTIN line)! It currently produces GMP with a content of JUST 1mg of phenylalanine (Phe) per 1 g of protein for PKU / HPA diet therapy.

AMINO ACID MIXTURES (AA) – PKU/HPA dietary therapy pioneer

IEM Allergy also offers AA mixtures for patients with PKU/HPA. In 2021, we began taking part in the research and development of PKU/HPA AA products (AntiFen range) with DMF Pharma. While it might appear that nothing can be improved in regard to AA products (perhaps apart from flavour or consistency), DMF Pharma has proven otherwise. Experts from DMF Pharma research discovered the new dimension of so-called negative PRAL (Potential Renal Acid Load). The negative PRAL of AntiFen products results in a significant reduction in risk of the most common comorbidities for patients with PKU/HPA (such as renal insufficiency, osteoporosis). More details on comorbidities for patients with PKU/HPA can be found here. DMF Pharma has patented its findings on negative PRAL.

We’re pleased to be able to introduce you to the cutting-edge GLYTACTIN (GMP) and AntiFen (AA) product lines.